Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
about
Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects.Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations.Targeting IL-17 in autoimmunity and inflammation.Erythrodermic psoriasis: pathophysiology and current treatment perspectives.The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis
P2860
Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
@en
type
label
Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
@en
prefLabel
Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
@en
P2093
P2860
P50
P1476
Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
@en
P2093
Alessia Alunno
Francesca Battista
Francesco Carubbi
Giacomo Pucci
Giuseppe Schillaci
Roberto Gerli
P2860
P304
P356
10.1517/14712598.2015.1084284
P407
P577
2015-09-07T00:00:00Z